AB680

DRUG4 trials

Sponsors

Arcus Biosciences, Inc.

Conditions

Advanced Pancreatic CancerHealthy VolunteersMetastatic Colorectal Cancer

Phase 1

A Study to Investigate the Safety of AB680 in Healthy Volunteers

CompletedNCT03677973

Arcus Biosciences, Inc.Healthy Volunteers

Start: 2018-10-16End: 2019-08-19Updated: 2024-05-24

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Active, not recruitingNCT04104672

Arcus Biosciences, Inc.Advanced Pancreatic Cancer

Start: 2019-11-06End: 2027-05-01Updated: 2026-03-31

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

CompletedNCT04575311

Arcus Biosciences, Inc.Healthy Volunteers

Start: 2020-10-20End: 2021-09-22Updated: 2024-05-24

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

CompletedNCT04660812

Arcus Biosciences, Inc.Metastatic Colorectal Cancer

Start: 2021-05-10End: 2025-09-05Updated: 2025-10-20

Related Papers

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Nature Medicine2026-03-30

The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer.

2026-03-23

Abstract C007: Quemliclustat (CD73 Inhibitor) reduces adenosine-regulated NR4A gene expression and increases mPDAC inflammation in patients from the ARC-8 trial

Cancer Research2024-09-152 citations

ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2024-06-017 citations

ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma.

Journal of Clinical Oncology2024-01-205 citations

AVALIAÇÃO DE NOVOS TRATAMENTOS PARA TUMORES SÓLIDOS QUE TIVERAM COMO ALVO A VIA ADENOSINÉRGICA

Hematology Transfusion and Cell Therapy2023-10-01

ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).

Journal of Clinical Oncology2021-01-2026 citations

A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies.

Journal of Clinical Oncology2020-02-018 citations

An Exceptionally Potent Inhibitor of Human CD73

Biochemistry2019-07-2356 citations